Skip Nav Destination
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
Issue Archive
November 14 2023
Table of Contents
INSIDE BLOOD ADVANCES
SYSTEMATIC REVIEWS

Comprehensive cancer treatment approach incorporating Social Determinants of Health. Created with BioRender.com.
CLINICAL TRIALS AND OBSERVATIONS
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Clinical Trials & Observations
Adam S. Zayac,Daniel J. Landsburg,Mitchell E. Hughes,Allison M. Bock,Grzegorz S. Nowakowski,Emily C. Ayers,Mark Girton,Marie Hu,Amy K. Beckman,Shaoying Li,L. Jeffrey Medeiros,Julie E. Chang,Adam Stepanovic,Habibe Kurt,Jose Sandoval-Sus,M. Ali Ansari-Lari,Shalin K. Kothari,Anna Kress,Mina L. Xu,Pallawi Torka,Suchitra Sundaram,Stephen D. Smith,Kikkeri N. Naresh,Yasmin H. Karimi,Narendranath Epperla,David A. Bond,Umar Farooq,Mahak Saad,Andrew M. Evens,Karan Pandya,Seema G. Naik,Manali Kamdar,Bradley Haverkos,Reem Karmali,Timothy S. Oh,Julie M. Vose,Heather Nutsch,Paul G. Rubinstein,Amina Chaudhry,Adam J. Olszewski
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
Clinical Trials & Observations
Farhad Ravandi,Asad Bashey,James Foran,Wendy Stock,Raya Mawad,Nicholas Short,Musa Yilmaz,Hagop Kantarjian,Olatoyosi Odenike,Anand Patel,Raman Garcha,William Barrett Ainsworth,Raphael Clynes,Jitendra Kanodia,Ying Ding,Huajiang Li,Steve Kye,Alice Mims
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
Clinical Trials & Observations
Nikhil Raghuram,Daisuke Hasegawa,Kentaro Nakashima,Syaza Rahman,Evangelia Antoniou,Torjus Skajaa,Pietro Merli,Anupam Verma,Karen R. Rabin,Catherine Aftandilian,Rishi S. Kotecha,Daniel Cheuk,Kirsi Jahnukainen,Alexandra Kolenova,Walentyna Balwierz,Alice Norton,Maureen O’Brien,Sonia Cellot,Ashley Chopek,Nira Arad-Cohen,Bianca Goemans,Marta Rojas-Vasquez,Hany Ariffin,Jack Bartram,E. Anders Kolb,Franco Locatelli,Jan-Henning Klusmann,Henrik Hasle,Bryan McGuire,Afia Hasnain,Lillian Sung,Johann Hitzler
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
Clinical Trials & Observations
Samuel Yamshon,Gui Zhen Chen,Caitlin Gribbin,Paul Christos,Bijal Shah,Stephen J. Schuster,Sonali M. Smith,Jakub Svoboda,Richard R. Furman,John P. Leonard,Peter Martin,Jia Ruan
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies
Clinical Trials & Observations
Belinda A. Campbell,Gabor Dobos,Zahra Haider,H. Miles Prince,Martine Bagot,Felicity Evison,Carrie van der Weyden,Chris McCormack,Caroline Ram-Wolff,Maryam Miladi,Julia J Scarisbrick
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
Clinical Trials & Observations
Sheila K. Pierson,Megan S. Lim,Gordan Srkalovic,Joshua D. Brandstadter,Mateo Sarmiento Bustamante,Saishravan Shyamsundar,Natalie Mango,Criswell Lavery,Bridget Austin,Daisy Alapat,Mary Jo Lechowicz,Adam Bagg,Hongzhe Li,Corey Casper,Frits van Rhee,David C. Fajgenbaum
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
Olivia Perez de Acha,Lauren Reiman,David S. Jayabalan,Zachary J. Walker,Grace Bosma,Alana L. Keller,Sarah E. Parzych,Diana Abbott,Beau M. Idler,Drew Ribadeneyra,Ruben Niesvizky,Peter A. Forsberg,Tomer M. Mark,Daniel W. Sherbenou
LYMPHOID NEOPLASIA
MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis
Alexia Katsarou,Nikolaos Trasanidis,Kanagaraju Ponnusamy,Ioannis V. Kostopoulos,Jaime Alvarez-Benayas,Foteini Papaleonidopoulou,Keren Keren,Pierangela M. R. Sabbattini,Niklas Feldhahn,Maria Papaioannou,Evdoxia Hatjiharissi,Ian M. Sudbery,Aristeidis Chaidos,Valentina S. Caputo,Anastasios Karadimitris
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
Clinical Trials & Observations
Jean Lemoine,Emmanuel Bachy,Guillaume Cartron,David Beauvais,Thomas Gastinne,Roberta Di Blasi,Marie-Thérèse Rubio,Stéphanie Guidez,Mohamad Mohty,Rene-Olivier Casasnovas,Magalie Joris,Cristina Castilla-Llorente,Corinne Haioun,Olivier Hermine,Michael Loschi,Sylvain Carras,Pierre Bories,Tom Fradon,Charles Herbaux,Pierre Sesques,Steven Le Gouill,Franck Morschhauser,Catherine Thieblemont,Roch Houot
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
Jackson T. Bowers,Jacob Anna,Steven M. Bair,Kaitlin Annunzio,Narendranath Epperla,Jerrin Joy Pullukkara,Sameh Gaballa,Michael A. Spinner,Shuning Li,Marcus R. Messmer,Joseph Nguyen,Emily C. Ayers,Charlotte B. Wagner,Boyu Hu,Mengyang Di,Scott F. Huntington,Fateeha Furqan,Nirav N. Shah,Christina Chen,Hatcher J. Ballard,Mitchell E. Hughes,Elise A. Chong,Sunita D. Nasta,Stefan K. Barta,Daniel J. Landsburg,Jakub Svoboda
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
Julia Driessen,Gerben J. C. Zwezerijnen,Heiko Schöder,Marie José Kersten,Alison J. Moskowitz,Craig H. Moskowitz,Jakoba J. Eertink,Martijn W. Heymans,Ronald Boellaard,Josée M. Zijlstra
MYELOID NEOPLASIA
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
Clinical Trials & Observations
Jorge Sierra,Pau Montesinos,Xavier Thomas,Laimonas Griskevicius,Thomas Cluzeau,Denis Caillot,Ollivier Legrand,Clara Minotti,Mario Luppi,Firas Farkas,Bourras-Rezki Bengoudifa,Geralyn Gilotti,Sejla Hodzic,Alessandro Rambaldi,Adriano Venditti
AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
Marius-Konstantin Klever,Eric Sträng,Sara Hetzel,Julius Jungnitsch,Anna Dolnik,Robert Schöpflin,Jens-Florian Schrezenmeier,Felix Schick,Olga Blau,Jörg Westermann,Frank G. Rücker,Zuyao Xia,Konstanze Döhner,Hubert Schrezenmeier,Malte Spielmann,Alexander Meissner,Uirá Souto Melo,Stefan Mundlos,Lars Bullinger
Long-term outcomes among adults with Langerhans cell histiocytosis
Gaurav Goyal,Aldo A. Acosta-Medina,Jithma P. Abeykoon,Chen Dai,Aishwarya Ravindran,Robert Vassallo,Jay H. Ryu,Mithun V. Shah,N. Nora Bennani,Jason R. Young,Corrie R. Bach,Gordon J. Ruan,Saurabh Zanwar,W. Oliver Tobin,Matthew J. Koster,Caroline J. Davidge-Pitts,Lucinda M. Gruber,Surendra Dasari,Karen L. Rech,Ronald S. Go,on behalf of the Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group
The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression
Youmna S. Kfoury,Fei Ji,Esha Jain,Michael Mazzola,Giulia Schiroli,Ani Papazian,Francois Mercier,David B. Sykes,Anna Kiem,Mark Randolph,Laura M. Calvi,Omar Abdel-Wahab,Ruslan I. Sadreyev,David T. Scadden
THROMBOSIS AND HEMOSTASIS
Crucial roles of red blood cells and platelets in whole blood thrombin generation
Siyu Sun,Elena Campello,Jinmi Zou,Joke Konings,Dana Huskens,Jun Wan,Delia I. Fernández,Chris P. M. Reutelingsperger,Hugo ten Cate,Serena Toffanin,Cristiana Bulato,Philip G. de Groot,Bas de Laat,Paolo Simioni,Johan W. M. Heemskerk,Mark Roest
TRANSPLANTATION
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
Clinical Trials & Observations
Wancheng Guo,Anne Zhan,David E. Mery,Manit N. Munshi,Oussama Makhoul,Clyde Baily,Maurizio Zangari,Guido Tricot,Hongling Peng,John D. Shaughnessy, Jr.
Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation
Lily M. Blair,Jamilla Akhund-Zade,Zoe A. Katsamakis,Olivia C. Smibert,Alex E. Wolfe,Paul Giardina,John Slingerland,Sivan Bercovici,Miguel-Angel Perales,Ying Taur,Marcel R. M. van den Brink,Jonathan U. Peled,Kate A. Markey
VASCULAR BIOLOGY
Platelets regulate ischemia-induced revascularization and angiogenesis by secretion of growth factor–modulating factors
Henry Nording,Lasse Baron,Manuela Sauter,Antje Lübken,Elias Rawish,Rebecca Szepanowski,Jacob von Esebeck,Ying Sun,Hossein Emami,Moritz Meusel,Roza Saraei,Nancy Schanze,Sivahari Prasad Gorantla,Nikolas von Bubnoff,Tobias Geisler,Philipp von Hundelshausen,Konstantinos Stellos,Jens Marquardt,Christian D. Sadik,Jörg Köhl,Daniel Duerschmied,Christoph Kleinschnitz,Harald F. Langer
RESEARCH LETTERS
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
Clinical Trials & Observations
Mary Figueroa,Huaxian Ma,Mansour Alfayez,Daniel Enrique Morales-Mantilla,Fei Wang,Yue Lu,Marcos R. Estecio,Katherine Y. King,Eugenie Kleinerman,Seyed Javad Moghaddam,Naval Daver,Michael Andreeff,Marina Konopleva,Courtney DiNardo,Joya Chandra
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
Janneke W. de Boer,Elise R. A. Pennings,Ankie Kleinjan,Jaap A. van Doesum,Anne M. Spanjaart,Pim G. N. J. Mutsaers,Margot Jak,Marjolein W. M. van der Poel,Maria T. Kuipers,Judit A. Adam,Arjan Diepstra,Lianne Koens,Suzanne van Dorp,Joost S. P. Vermaat,Anne G. H. Niezink,Marie José Kersten,Tom van Meerten
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
Clinical Trials & Observations
Alessandro Broccoli,Lisa Argnani,Laura Nanni,Vittorio Stefoni,Cinzia Pellegrini,Beatrice Casadei,Gabriele Gugliotta,Matteo Carella,Paolo Elia Coppola,Gianmarco Bagnato,Pier Luigi Zinzani
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
Clinical Trials & Observations
Paolo Strati,Andrew Jallouk,Qing Deng,Xubin Li,Lei Feng,Ryan Sun,Sherry Adkins,Swapna Johncy,Taylor Cain,Raphael E. Steiner,Sairah Ahmed,Dai Chihara,Luis E. Fayad,Swaminathan P. Iyer,Sandra Horowitz,Loretta J. Nastoupil,Ranjit Nair,Ahmed Hassan,Taher E. Daoud,Misha Hawkins,Maria A. Rodriguez,Elizabeth J. Shpall,Jeremy L. Ramdial,Partow Kebriaei,David S. Hong,Jason R. Westin,Sattva S. Neelapu,Michael R. Green
COMMENTARIES
RESPONSE
ERRATUM
-
Cover Image
Cover Image
Stem cells on a scientific background. ID 132782140 © Stanislav Rykunov| Dreamstime.com
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals
ICANS prophylaxis: potentially transformative but elusive
Clinical Trials & Observations